294 related articles for article (PubMed ID: 34255901)
1. Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.
Gao Y; Guo J; Bao X; Xiong F; Ma Y; Tan B; Yu L; Zhao Y; Lu J
Oncologist; 2021 Nov; 26(11):e1919-e1930. PubMed ID: 34255901
[TBL] [Abstract][Full Text] [Related]
2. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
Exley MA; Friedlander P; Alatrakchi N; Vriend L; Yue S; Sasada T; Zeng W; Mizukami Y; Clark J; Nemer D; LeClair K; Canning C; Daley H; Dranoff G; Giobbie-Hurder A; Hodi FS; Ritz J; Balk SP
Clin Cancer Res; 2017 Jul; 23(14):3510-3519. PubMed ID: 28193627
[No Abstract] [Full Text] [Related]
3. Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma.
Cheng X; Tan X; Wang W; Zhang Z; Zhu R; Wu M; Li M; Chen Y; Liang Z; Zhu P; Wu X; Weng X
Cancer Res; 2023 Feb; 83(4):582-594. PubMed ID: 36512635
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
5. Decrease of spleen invariant natural killer T and natural killer cell numbers in Burkholderia thailandensis-infected C57BL/6 mice.
Kasetthat T; Sermswan RW; Ren Y; Watarai H; Wongratanacheewin S
Asian Pac J Allergy Immunol; 2022 Jun; 40(2):155-161. PubMed ID: 31586487
[TBL] [Abstract][Full Text] [Related]
6. Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.
Hsu CY; Chueh YS; Kuo ML; Lee PT; Hsiao HS; Huang JL; Lin SJ
PLoS One; 2021; 16(12):e0261727. PubMed ID: 34936686
[TBL] [Abstract][Full Text] [Related]
7. Activation of invariant natural killer T cells in regional lymph nodes as new antigen-specific immunotherapy via induction of interleukin-21 and interferon-γ.
Sakurai T; Inamine A; Iinuma T; Funakoshi U; Yonekura S; Sakurai D; Hanazawa T; Nakayama T; Ishii Y; Okamoto Y
Clin Exp Immunol; 2014 Oct; 178(1):65-74. PubMed ID: 24943738
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial.
Guo J; Bao X; Liu F; Guo J; Wu Y; Xiong F; Lu J
J Hepatocell Carcinoma; 2023; 10():1379-1388. PubMed ID: 37637501
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
Takami M; Ihara F; Motohashi S
Front Immunol; 2018; 9():2021. PubMed ID: 30245690
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
[TBL] [Abstract][Full Text] [Related]
11. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments.
Lee IC; Huang YH; Chau GY; Huo TI; Su CW; Wu JC; Lin HC
Int J Cancer; 2013 Dec; 133(12):2895-902. PubMed ID: 23749461
[TBL] [Abstract][Full Text] [Related]
12. Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1
Wang J; Cheng X; Jin Y; Xia B; Qin R; Zhang W; Hu H; Mao X; Zhou L; Yan J; Zhang X; Xu J
Cancer Res Commun; 2023 Jun; 3(6):991-1003. PubMed ID: 37377605
[TBL] [Abstract][Full Text] [Related]
13. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
Song W; van der Vliet HJ; Tai YT; Prabhala R; Wang R; Podar K; Catley L; Shammas MA; Anderson KC; Balk SP; Exley MA; Munshi NC
Clin Cancer Res; 2008 Nov; 14(21):6955-62. PubMed ID: 18980990
[TBL] [Abstract][Full Text] [Related]
14. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
Yang G; Artiaga BL; Lewis ST; Driver JP
Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168
[TBL] [Abstract][Full Text] [Related]
15. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
16. In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells.
Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Clin Immunol; 2008 Oct; 129(1):145-54. PubMed ID: 18707922
[TBL] [Abstract][Full Text] [Related]
17. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
[TBL] [Abstract][Full Text] [Related]
18. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.
Ohira M; Hotta R; Tanaka Y; Matsuura T; Tekin A; Selvaggi G; Vianna R; Ricordi C; Ruiz P; Nishida S; Tzakis AG; Ohdan H
Cancer Immunol Immunother; 2022 Mar; 71(3):589-599. PubMed ID: 34282496
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F; Zhao J; Tan AT; Hu W; Wang SY; Jin J; Wu J; Li Y; Shi L; Fu JL; Yu S; Shen Y; Liu L; Luan J; Shi M; Xie Y; Zhou CB; Wong RW; Lu-En W; Koh S; Bertoletti A; Wang T; Zhang JY; Wang FS
Hepatol Int; 2021 Dec; 15(6):1402-1412. PubMed ID: 34850325
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.
Bae WK; Lee BC; Kim HJ; Lee JJ; Chung IJ; Cho SB; Koh YS
Front Immunol; 2022; 13():879452. PubMed ID: 35720374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
